Want to see DNTH full AI Analyst Report?
Dianthus Therapeutics (DNTH) Ratios
445 Followers
Dianthus Therapeutics Ratios
DNTH's free cash flow for Q3 2026 was $-50.70M. For the 2026 fiscal year, DNTH's free cash flow was decreased by $-368.00K and operating cash flow was $-50.33M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 |
| Quick Ratio | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 |
| Cash Ratio | 1.66 | 1.24 | 13.74 | 1.87 | 12.12 |
| Solvency Ratio | -4.32 | -3.93 | -4.10 | -3.00 | -0.76 |
| Operating Cash Flow Ratio | -4.20 | -4.24 | -3.83 | -3.53 | -5.48 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 371.92M | $ 259.37M | $ 166.92M | $ 72.58M | $ 163.43M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.08 | 1.06 | 1.06 | 1.13 | 1.10 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.04 | 0.04 | 0.11 | 0.21 | 0.00 |
| Net Debt to EBITDA | 0.31 | 0.25 | 2.75 | 0.49 | 10.06 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -7973.33% | -1362.77% | -1704.67% | -462.91% | -886.59% |
| EBITDA Margin | -7952.31% | -1356.17% | -1692.11% | -460.62% | -886.59% |
| Operating Profit Margin | -8739.34% | -1633.74% | -1704.67% | -462.91% | -886.59% |
| Pretax Profit Margin | -7973.33% | -1362.77% | -1541.22% | -443.76% | -888.14% |
| Net Profit Margin | -7973.33% | -1362.77% | -1541.22% | -443.76% | -888.14% |
| Continuous Operations Profit Margin | -7973.33% | -1362.77% | -1541.22% | -443.76% | -888.14% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 91.23% | 83.41% | 90.41% | 95.86% | 100.18% |
| Return on Assets (ROA) | -30.58% | -22.72% | -24.28% | -34.26% | -6.90% |
| Return on Equity (ROE) | -32.90% | -24.11% | -25.79% | -38.66% | -7.59% |
| Return on Capital Employed (ROCE) | -35.57% | -28.65% | -28.38% | -39.67% | -7.31% |
| Return on Invested Capital (ROIC) | -35.55% | -28.62% | -28.31% | -39.48% | -7.31% |
| Return on Tangible Assets | -30.58% | -22.72% | -24.28% | -34.26% | -6.90% |
| Earnings Yield | -10.42% | -11.70% | -81.27% | -120.24% | -5.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 19.96 | 7.73 | 5.91 | 1.14 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.25 | 3.57 | 3.53 | 6.71 | 0.20 |
| Asset Turnover | 0.00 | 0.02 | 0.02 | 0.08 | 0.01 |
| Working Capital Turnover Ratio | 0.01 | 0.03 | 0.02 | 0.05 | 0.01 |
| Cash Conversion Cycle | 18.29 | 47.24 | 61.74 | 320.69 | 0.00 |
| Days of Sales Outstanding | 18.29 | 47.24 | 61.74 | 320.69 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 18.29 | 47.24 | 61.74 | 320.69 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.41 | -2.35 | -7.15 | -7.76 | -17.33 |
| Free Cash Flow Per Share | -3.42 | -2.35 | -7.17 | -7.79 | -17.70 |
| Dividend Paid and CapEx Coverage Ratio | -605.92 | -744.57 | -335.10 | -209.14 | -47.10 |
| Capital Expenditure Coverage Ratio | -605.92 | -744.57 | -335.10 | -209.14 | -47.10 |
| Operating Cash Flow Coverage Ratio | -93.12 | -52.43 | -63.01 | -36.89 | 0.00 |
| Operating Cash Flow to Sales Ratio | -63.39 | -12.54 | -13.04 | -4.53 | -40.33 |
| Free Cash Flow Yield | -8.30% | -10.78% | -68.98% | -123.34% | -24.98% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -9.81 | -8.55 | -1.23 | -0.83 | -18.57 |
| Price-to-Sales (P/S) Ratio | 764.98 | 116.48 | 18.97 | 3.69 | 164.92 |
| Price-to-Book (P/B) Ratio | 3.16 | 2.06 | 0.32 | 0.32 | 1.41 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -12.05 | -9.28 | -1.45 | -0.81 | -4.00 |
| Price-to-Operating Cash Flow Ratio | -12.07 | -9.29 | -1.45 | -0.81 | -4.09 |
| Price-to-Earnings Growth (PEG) Ratio | -0.15 | 0.12 | -0.11 | -0.01 | 0.22 |
| Enterprise Value Multiple | -9.31 | -8.34 | 1.63 | -0.31 | -8.54 |
| Enterprise Value | 1.51B | 704.94M | -78.14M | 9.11M | 111.77M |
| EV to EBITDA | -9.31 | -8.34 | 1.63 | -0.31 | -8.54 |
| EV to Sales | 740.57 | 113.06 | -27.65 | 1.42 | 75.73 |
| EV to Free Cash Flow | -11.66 | -9.00 | 2.11 | -0.31 | -1.84 |
| EV to Operating Cash Flow | -11.68 | -9.02 | 2.12 | -0.31 | -1.88 |
| Tangible Book Value Per Share | 13.05 | 10.58 | 32.77 | 19.66 | 50.28 |
| Shareholders’ Equity Per Share | 13.05 | 10.58 | 32.77 | 19.66 | 50.28 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.05 | 0.19 | 0.55 | 1.71 | 0.43 |
| Net Income Per Share | -4.30 | -2.55 | -8.45 | -7.60 | -3.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 0.96 | 1.00 |
| Research & Development to Revenue | 71.53 | 13.33 | 11.62 | 4.58 | 8.54 |
| SG&A to Revenue | 16.86 | 4.01 | 6.43 | 1.05 | 1.33 |
| Stock-Based Compensation to Revenue | 11.19 | 2.07 | 1.03 | 0.24 | 0.00 |
| Income Quality | 0.80 | 0.92 | 0.85 | 1.02 | 0.84 |
Currency in USD
